Arcellx (NASDAQ:ACLX) Rating Lowered to “Hold” at Truist Financial

Arcellx (NASDAQ:ACLX) was downgraded by analysts at Truist Financial from a “buy” rating to a “hold” rating in a research report issued on Monday, Marketbeat Ratings reports. They presently have a $120.00 price target on the stock, down from their prior price target of $134.00. Truist Financial’s price objective suggests a potential upside of 5.53% from the company’s previous close.

Several other research firms have also commented on ACLX. Citigroup lowered Arcellx from a “buy” rating to a “neutral” rating and boosted their price target for the stock from $110.00 to $115.00 in a research report on Tuesday. Rothschild & Co Redburn lowered shares of Arcellx from a “buy” rating to a “neutral” rating and set a $82.00 price objective on the stock. in a research note on Thursday, February 12th. HC Wainwright downgraded shares of Arcellx from a “buy” rating to a “neutral” rating and set a $115.00 target price for the company. in a research note on Monday. William Blair lowered shares of Arcellx from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, UBS Group downgraded shares of Arcellx from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $100.00 to $115.00 in a research note on Tuesday. Two research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $111.64.

Arcellx Price Performance

Shares of ACLX opened at $113.71 on Monday. Arcellx has a 12 month low of $47.86 and a 12 month high of $114.26. The stock’s 50-day moving average is $68.84 and its two-hundred day moving average is $75.38. The stock has a market cap of $6.57 billion, a PE ratio of -28.93 and a beta of 0.36.

Insider Activity

In related news, insider Christopher Heery sold 5,882 shares of Arcellx stock in a transaction on Wednesday, January 14th. The shares were sold at an average price of $68.51, for a total value of $402,975.82. Following the completion of the sale, the insider owned 23,749 shares in the company, valued at approximately $1,627,043.99. The trade was a 19.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 19,450 shares of company stock valued at $1,283,477 in the last three months. 8.35% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. MAI Capital Management acquired a new stake in shares of Arcellx in the 3rd quarter valued at about $26,000. CWM LLC grew its stake in Arcellx by 267.0% in the third quarter. CWM LLC now owns 345 shares of the company’s stock worth $28,000 after purchasing an additional 251 shares in the last quarter. State of Wyoming bought a new stake in Arcellx in the second quarter valued at about $28,000. Ramirez Asset Management Inc. bought a new position in Arcellx during the 3rd quarter worth approximately $41,000. Finally, PNC Financial Services Group Inc. grew its position in shares of Arcellx by 183.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 751 shares of the company’s stock worth $49,000 after acquiring an additional 486 shares in the last quarter. 96.03% of the stock is owned by institutional investors and hedge funds.

Key Arcellx News

Here are the key news stories impacting Arcellx this week:

• Positive Sentiment: Gilead Sciences agreed to acquire Arcellx for $115.00 per share in cash plus one contingent value right worth $5.00 if milestones are met, implying up to ~$7.8 billion — a takeover premium that drove a large rally. Gilead acquisition release
• Positive Sentiment: Market reaction: the deal triggered a premarket surge (roughly 75–80% intraday move at announcement) and sharply elevated trading volumes as the market re‑priced ACLX to reflect the cash consideration. Reuters coverage
• Neutral Sentiment: HC Wainwright updated FY2030 EPS expectations materially (analyst projects $4.95/sh) but kept a “Neutral” rating and $115 price objective — effectively aligned with the deal price and not implying incremental upside beyond the offer. MarketBeat report
• Negative Sentiment: Multiple brokerages downgraded ACLX to “hold”/”equal weight” (Truist, Baird, Canaccord, Needham, Wells Fargo, Citigroup), signaling limited upside above the deal price and reducing buy‑side conviction. Example coverage: Truist/Benzinga. Benzinga downgrades roundup
• Negative Sentiment: Several law firms (Kahn Swick & Foti, Halper Sadeh, Ademi, Monteverde) announced investigations into whether the $115 + $5 CVR consideration is fair — potential litigation could seek a higher price, delay closing or increase transaction risk/uncertainty. KSF investor alert

About Arcellx

Arcellx, Inc (NASDAQ: ACLX) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company’s proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.

The company’s pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.